Europe's First Disease-Modifying Therapy for Type 1 Diabetes

The European Medicines Agency (EMA) has granted final marketing authorization for Teizeild (teplizumab), a CD3-directed monoclonal antibody developed by Sanofi (SNY), as a treatment to delay the onset of stage 3 type 1 diabetes (T1D) in patients aged 8 years and older. This approval, granted on January 8, 2026, marks a significant milestone, occurring approximately three years after the U.S. Food and Drug Administration (FDA) approved the same drug, marketed as Tzield, in November 2022. Teizeild is administered intravenously once daily for 14 consecutive days and works by inhibiting the destruction of insulin-producing pancreatic beta cells, thereby delaying the progression of diabetes. By introducing the first disease-modifying therapy (DMT) that goes beyond conventional insulin replacement, Teizeild is poised to fundamentally change the paradigm of diabetes management in Europe.

Innovative Efficacy Demonstrated in the TN-10 Clinical Trial

This approval is based on the results of the TN-10 study, a pivotal phase 2 clinical trial conducted in a high-risk population. Clinical data showed that patients receiving Teizeild experienced a delay of approximately 2 years (24 months) in the median time to the diagnosis of stage 3 type 1 diabetes, compared to the placebo group, with a maximum delay of up to 32.5 months. In contrast to the placebo group, which had a median time to diagnosis of 24.4 to 27.1 months, the Teizeild group demonstrated a clinically significant delay in disease progression, with the disease being suppressed for 48.4 to 59.6 months. This delay can postpone the need for daily insulin injections and strict blood sugar management for several years, offering significant medical benefits and improving the quality of life (QoL) for pediatric patients and their families.

Sanofi's Strategic Acquisition of Provention Bio

In April 2023, Sanofi acquired Provention Bio, the original developer of Teizeild, for $25.00 per share, totaling approximately $2.9 billion in cash, securing full ownership of the pipeline. This acquisition, which superseded a co-promotion agreement signed in 2022, allows Sanofi to further strengthen its market position in the immunology and diabetes fields. This aggressive merger and acquisition (M&A) strategy exemplifies how global pharmaceutical companies are securing innovative drugs with blockbuster potential early on to diversify their biologics portfolios and drive growth.

Market Expansion and Commercial Challenges in Patient Identification

According to global market research firms, Teizeild's global peak sales are projected to reach approximately $579 million by 2035. While initial expectations pointed to blockbuster status with annual sales exceeding $1 billion, the lack of a robust large-scale diagnostic screening system to identify asymptomatic stage 2 patients is hindering market growth. Sanofi is heavily investing in autoantibody screening and disease awareness campaigns to improve diagnostic rates and is also seeking to expand the indication to include children under the age of 8 to further expand the addressable market.